Data from six US centers indicated that CD19 CAR-T therapy for patients with CNS involvement in diffuse large B-cell lymphoma (DLBCL) achieved a 92% CR rate at three months, with only 8% of patients experiencing PD. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.